{"schema_version":"secwatch.filing_event.v1","accession":"0001200375-24-000013","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.575279+00:00","generated_at":"2026-06-02T23:58:05.768181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Codexis Q1 revenue up 32%, net loss narrows to $11.5M; reiterates FY guidance","bullets":["Total revenue $17.1M (+32% YoY); product revenue $9.6M (+14%); net loss $11.5M vs $22.6M loss in Q1 2023.","Received first large pharma order for dsRNA ligase (low-to-mid single digit million) and entered $40M loan facility with Innovatus.","Reiterated FY 2024 guidance: product rev $38-42M, R&D rev $18-22M, product gross margin 58-63%.","Cash and investments $85.5M; expects to fund operations through positive cash flow by end of 2026.","Exclusive license with Roche for dsDNA ligase; sold HCU and MSUD compounds."],"urls":{"canonical":"https://secwatch.observer/filing/0001200375-24-000013","json":"https://secwatch.observer/filing/0001200375-24-000013.json","markdown":"https://secwatch.observer/filing/0001200375-24-000013.md","text":"https://secwatch.observer/filing/0001200375-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/0001200375-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/cdxs-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:58:05.768181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a80847062f3e15e2c6e9724daa89c4ef8d6275c","claim":"CODEXIS, INC. reported the first quarter ended March 31, 2024 results: revenue $17.1 million. Guidance reaffirmed.","evidence_excerpt":"in the second half of 2025, ahead of an anticipated full commercial launch of the platform in 2026. First Quarter 2024 Financial Highlights • Total revenues increased by 32% to $17.1 million for first quarter 2024 compared to $13.0 million in first quarter 2023. • Product revenues increased by 14% to $9.6 million for first quarter 2024 compared to $8.4 million in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/0001200375-24-000013-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$17.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}